Cargando…

High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen

PURPOSE: This study aimed to investigate the prevalence of resistance to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based single-tablet regimen (STR) in Taiwanese patients and clarify the clinical implications of using doravirine in patients who fail NNRTI treatment. PATIENTS AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Hung-Chin, Chen, I-Tzu, Chang, Hui-Min, Lee, Susan Shin-Jung, Chen, Yao-Shen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309287/ https://www.ncbi.nlm.nih.gov/pubmed/35899084 http://dx.doi.org/10.2147/IDR.S361012

Ejemplares similares

HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan
por: Tsai, Hung-Chin, et al.
Publicado: (2018)

Trend of HIV Transmitted Drug Resistance After the Introduction of Single-Tablet Regimens in Southern Taiwan
por: Tsai, Hung-Chin, et al.
Publicado: (2022)

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa
por: Kityo, Cissy, et al.
Publicado: (2017)

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens
por: Kapadia, Shashi N, et al.
Publicado: (2018)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
por: Bunupuradah, Torsak, et al.
Publicado: (2011)

Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load
por: Kibalama Ssemambo, Phionah, et al.
Publicado: (2021)

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients
por: Gatell, Josep M, et al.
Publicado: (2014)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin
por: Mankhatitham, W, et al.
Publicado: (2010)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

1590. Resistance to Etravirine, Doravine and Rilpivirine in People Living with HIV Experiencing Virologic Failure to a First-line Antiretroviral Regimen Based on a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in a Latin American Country.
por: Mingrone, Verónica, et al.
Publicado: (2023)

Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting
por: Chang, Hui-Min, et al.
Publicado: (2022)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya
por: Beck, Ingrid A., et al.
Publicado: (2020)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens
por: Wiesmann, Frank, et al.
Publicado: (2014)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

1011. Efficacy and Safety of Doravirine in Treatment-Naïve Adults ≥50 Years Old With HIV-1
por: Mills, Anthony, et al.
Publicado: (2020)

Single-Tablet Regimens in HIV Therapy
por: Astuti, Noemi, et al.
Publicado: (2014)

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
por: Aragão, F, et al.
Publicado: (2010)

Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
por: Beck, Eduard J., et al.
Publicado: (2011)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naïve Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan
por: Tsai, Hung-Chin, et al.
Publicado: (2020)

Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan
por: Weng, Ya-Wei, et al.
Publicado: (2019)

Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Naïve HIV-1 Positive Adults: A Bayesian Network Meta-Analysis
por: Zhang, Ke, et al.
Publicado: (2022)

Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
por: Rock, Alexander E, et al.
Publicado: (2020)

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2015)

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
por: Rhee, Soo-Yon, et al.
Publicado: (2023)

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
por: Johnson, Margaret, et al.
Publicado: (2019)

High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs
por: Ha, Betty, et al.
Publicado: (2021)

Transmitted Drug Resistance in Treatment-naïve HIV-Infected VCT clients in Taiwan, 2007–2016
por: Tsai, Hung-Chin, et al.
Publicado: (2017)

High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014
por: Tsai, Hung-Chin, et al.
Publicado: (2017)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients
por: Bossard, Claire, et al.
Publicado: (2021)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting
por: Chehadeh, Wassim, et al.
Publicado: (2020)

Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis
por: Mazzitelli, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_07vof569mr1mih2pc4ctk3dabq